Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
---|---|---|---|---|---|---|
|
genotype assessment | Gpr84 allele assessment. PCR, sequencing. | inbred w/CC8 (58) | both | 6wks | 2013 |
|
genotyping | SNP profiling, 131,000+ genomic locations, 1-19,X. | inbred (89) | 2009 | ||
|
genotyping | SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. | inbred (142) | m | 2014 | |
|
body size and weight | Body weight and length. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
complete blood count | Hematology. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
DXA | Body mass, fat mass, lean mass, bone mineral density. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred w/CC8 (72) | both | 10-13wks | 2009 |
|
body weight
with isoniazid |
Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
histopathology
with isoniazid |
Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
lipid profile
with isoniazid |
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
metabolic panel
with isoniazid |
Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
organ weights
with isoniazid |
Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
biomarker quantification
with DB289 |
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
body weight
with DB289 |
DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
drug and metabolite quantification
with DB289 |
Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
metabolic panel
with DB289 |
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
organ weights
with DB289 |
Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
urinalysis
with DB289 |
Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
MHC haplotype tissue typing | Major histocompatibility complex (MHC) H2 haplotype. | inbred (56) | both | 2000 | |
|
ABR test | Auditory brainstem response. | inbred (51) | both | 3-12wks and 15-72wks | 2000 |
|
open field test | Distance traveled, after first 10 min and after 55 min. | other (58) | both | 7-26wks | 2019 |
|
body weight | Body weight | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
open field test | Locomotor activity and grooming behavior. | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
body size and weight | Body length measurements. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
gait analysis | Angular velocity, Stride speed, Step length, Step width, and other gait metrics. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
open field test | Distance traveled. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
body weight | Body weight | inbred (32) | m | 7-9wks | 2007 |
|
hormone quantification | Corticosterone (serum). | inbred (32) | m | 7-9wks | 2007 |
|
open field test | Locomotor and anxiety-related behavior. 10 min test. | inbred (32) | m | 7-9wks | 2007 |
|
tail suspension test | Immobility percentage. | inbred (32) | m | 7-9wks | 2007 |
|
body weight
with cocaine |
Body weight | inbred (45) | m | 8-11wks | 2015 |
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 |
|
forced swim test
with ovariectomy |
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. | inbred (37) | f | 8-10wks | 2016 |
|
open field test
with ovariectomy |
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. | inbred (37) | f | 8-10wks | 2016 |
|
genotyping | SNP profiling, 132,000+ genomic locations, 1-19,X | HMDP (248) | both | 2018 | |
|
elevated plus maze | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
light-dark box | Light-dark test. Anxiety-related behavior. | inbred (38) | both | 12-14wks | 2010 |
|
open field test | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
drug and metabolite quantification
with fluoxetine |
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 |
|
open field test
with fluoxetine |
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. | inbred (30) | m | 9-11wks | 2011 |
|
tail suspension test
with fluoxetine |
Immobility. Fluoxetine-treated vs. control. 5 min test. | inbred (30) | m | 9-11wks | 2011 |
|
biomarker quantification
with fluoxetine |
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 |
|
tympanometry | Middle ear function. | inbred (61) | both | 15-51d | 2008 |